The British journal of ophthalmology · 2024
Low-dose atropine 0.01% for the treatment of childhood myopia: a pan-India multicentric retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saxena Rohit, Gupta Vinay, Dhiman Rebika, Joseph Elizabeth, Agarkar Sumita, Neena R, Magdalene Damaris, Jethani Jitendra, Ganesh Sandra C, Patil Minal, Gogri Pooja, Gadaginamath Shailesh, Sen Pradhnya, Sukhija Jaspreet, Mishra Deepak, Matalia Jyoti H, Sahu Anupam, Kapoor Smita, Nishanth Shruti, Chaurasia Shweta, Pawar Neelam, Deori Nilutparna, Sivaraman Viswanathan, Bordoloi Anamika, Tibrewal Shailja, Singh Davinder, Prasad Priyanka, Phuljhele Swati, Sharma Namrata
Аннотация
OBJECTIVE: The objective of this study was to assess the efficacy of low-dose atropine 0.01% in controlling myopia progression among Indian children over a 2-year period.
METHODS: This retrospective study, conducted across 20 centres in India, monitored the progression of myopia over 2 years after initiating treatment with 0.01% atropine eye drops. This included children between 6 and 14 years with baseline myopia ranging from -0.5 D to -6 D, astigmatism≤-1.5 D, anisometropia ≤ -1 D and documented myopia progression of ≥0.5 D in the year prior to starting atropine. Subjects with any other ocular pathologies were excluded.
RESULTS: A total of 732 children were included in the data analysis. The mean age of the subjects was 9.3±2.7 years. The mean myopia progression at baseline (1 year before starting atropine) was -0.75±0.31 D. The rate of myopia progression was higher in younger subjects and those with higher baseline myopic error. After initiating atropine, myopia progression significantly decreased to -0.27±0.14 D at the end of the first year and -0.24±0.15 D at the end of the second year (p<0.001). Younger children (p<0.001) and higher baseline myopia (p<0.001) was associated with greater myopia progression and poor treatment response (p<0.001 for both).
CONCLUSION: Low-dose atropine (0.01%) effectively reduces myopia progression over 2 years in Indian children.
METHODS: This retrospective study, conducted across 20 centres in India, monitored the progression of myopia over 2 years after initiating treatment with 0.01% atropine eye drops. This included children between 6 and 14 years with baseline myopia ranging from -0.5 D to -6 D, astigmatism≤-1.5 D, anisometropia ≤ -1 D and documented myopia progression of ≥0.5 D in the year prior to starting atropine. Subjects with any other ocular pathologies were excluded.
RESULTS: A total of 732 children were included in the data analysis. The mean age of the subjects was 9.3±2.7 years. The mean myopia progression at baseline (1 year before starting atropine) was -0.75±0.31 D. The rate of myopia progression was higher in younger subjects and those with higher baseline myopic error. After initiating atropine, myopia progression significantly decreased to -0.27±0.14 D at the end of the first year and -0.24±0.15 D at the end of the second year (p<0.001). Younger children (p<0.001) and higher baseline myopia (p<0.001) was associated with greater myopia progression and poor treatment response (p<0.001 for both).
CONCLUSION: Low-dose atropine (0.01%) effectively reduces myopia progression over 2 years in Indian children.